A detailed history of Deutsche Bank Ag\ transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 560,873 shares of CGEM stock, worth $7.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
560,873
Previous 555,067 1.05%
Holding current value
$7.54 Million
Previous $9.68 Million 3.01%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$16.03 - $20.86 $93,070 - $121,113
5,806 Added 1.05%
560,873 $9.39 Million
Q2 2024

Aug 14, 2024

BUY
$15.63 - $29.35 $90,513 - $169,965
5,791 Added 1.05%
555,067 $9.68 Million
Q1 2024

May 15, 2024

BUY
$10.17 - $19.02 $37,547 - $70,221
3,692 Added 0.68%
549,276 $9.36 Million
Q4 2023

Feb 14, 2024

BUY
$7.89 - $10.23 $4.27 Million - $5.53 Million
540,967 Added 11716.85%
545,584 $5.56 Million
Q3 2023

Nov 09, 2023

SELL
$9.05 - $11.72 $33,267 - $43,082
-3,676 Reduced 44.33%
4,617 $41,000
Q2 2023

Aug 14, 2023

SELL
$8.8 - $13.4 $67,496 - $102,778
-7,670 Reduced 48.05%
8,293 $89,000
Q1 2023

May 15, 2023

BUY
$10.2 - $11.91 $37,270 - $43,519
3,654 Added 29.69%
15,963 $163,000
Q4 2022

Feb 13, 2023

BUY
$9.72 - $13.62 $1,982 - $2,778
204 Added 1.69%
12,309 $129,000
Q3 2022

Nov 14, 2022

SELL
$11.82 - $15.42 $23,557 - $30,732
-1,993 Reduced 14.14%
12,105 $155,000
Q2 2022

Aug 11, 2022

SELL
$7.31 - $13.55 $1,929 - $3,577
-264 Reduced 1.84%
14,098 $181,000
Q1 2022

May 13, 2022

SELL
$10.47 - $16.75 $17,401 - $27,838
-1,662 Reduced 10.37%
14,362 $150,000
Q4 2021

Feb 11, 2022

BUY
$15.36 - $25.0 $12,625 - $20,550
822 Added 5.41%
16,024 $247,000
Q3 2021

Nov 04, 2021

BUY
$22.56 - $29.68 $155,257 - $204,257
6,882 Added 82.72%
15,202 $343,000
Q2 2021

Aug 11, 2021

SELL
$24.96 - $41.25 $6,539 - $10,807
-262 Reduced 3.05%
8,320 $214,000
Q1 2021

May 13, 2021

BUY
$28.0 - $53.42 $240,296 - $458,450
8,582 New
8,582 $357,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $613M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.